CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-01 | Whitfill Travis Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2022-06-01 | Roemer Alan S. Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2022-06-01 | Greenwood Luba Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2022-06-01 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2022-06-01 | Brandt Peter C. Director | Grant or award · Stock Option (right to buy) | +13,500 | 13,500 | ||
| 2022-06-01 | Brandt Peter C. Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2022-06-01 | FAIRBAIRN EMILY Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2022-06-01 | Greenwood Luba Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2022-06-01 | Roemer Alan S. Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2022-06-01 | Whitfill Travis Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2022-05-05 | Lamb Lawrence EVP and CSO | Exercise or conversion | +26,204 | $1.07 | $28K | 99,204 |
| 2022-05-05 | Lamb Lawrence EVP and CSO | Exercise or conversion · Employee Stock Option (right to buy) | −26,204 | 1,171 | ||
| 2022-02-15 | McCall Patrick Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +84,500 | 84,500 | ||
| 2022-02-15 | Goswami Trishna Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +90,500 | 90,500 | ||
| 2022-02-15 | Lamb Lawrence EVP and CSO | Grant or award · Employee Stock Option (right to buy) | +62,500 | 62,500 | ||
| 2022-02-15 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +96,000 | 96,000 | ||
| 2022-02-15 | Ho William Tai-Wei President, CEO and CFO | Grant or award · Employee Stock Option (right to buy) | +254,500 | 254,500 | ||
| 2021-11-19 | Roemer Alan S. Director | Grant or award · Stock Option (right to buy) | +86,258 | 86,258 | ||
| 2021-11-19 | Goswami Trishna Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2021-08-13 | Kreis Leslie W. 10% owner | Other acquisition · Stock Option (right to buy) | +12,775 | 12,775 |
Page 13 of 16 · 309 trades